Primary leiomyosarcoma of the male urethra: a case report
© Ahallal et al; licensee BioMed Central Ltd. 2009
Received: 19 October 2009
Accepted: 18 November 2009
Published: 18 November 2009
Cancers of the male urethra constitute less than 1% of all malignant urological tumours, and the occurrence of sarcomas in the urethra is even less frequent. To our knowledge, only one case has been previously described in the English literature.
We report the clinical features, histology, imaging and treatment of urethral leiomyosarcoma in a male patient.
The occurrence of sarcoma in the urethra is most unusual, and its appearance as a primary growth in the male urethra is not recorded in the English literature. In conclusion, this case highlights a rare type of primary male urethral malignancy that features a poor prognosis.
Primary sarcoma of the urethra in the male patient is extremely rare. Malignant neoplasms of the urethra are typically squamous cell carcinoma. Leiomyosarcoma is a very rare neoplasm of the urinary system with less than 20 cases being reported in the literature up to date.
We report below the case of a male patient with ureteral leiomyosarcoma.
Leiomyosarcoma is a rare soft-tissue tumor that accounts for 10-20% of soft-tissue sarcoma. It is generally seen in middle-aged patients, and affects women more frequently than men . Its usual locations, in order of decreasing frequency are: retroperitoneal, intra-abdominal, cutaneous and subcutaneous. Leiomyosarcoma is a highly malignant tumor with an extremely poor prognosis. The 5-year overall survival rate in patients with soft-tissue sarcoma of all stages remains poor, at only 50-60%, and 5-year disease-free survival is rare. To our knowledge, only 1 case of urethral leiomyosarcoma has been previously reported. Wide local excision is considered to be the treatment of choice with radiation and chemotherapy being offered to patients with positive margins or nodes, or those with bulky disease [2, 3]. If anatomically feasible, radiotherapy can be considered for larger tumors and/or positive margins. Adjuvant chemotherapy has not been proven to be effective and remains investigational.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Cotran RS, Kumar V, Collins T: Robbins Pathologic Basis of Disease. 1999, Philadelphia: WB Saunders, 1259-1267. 6Google Scholar
- Maruyama E, Azuma H, Yamamoto K, Katsuoka Y: Retroperitoneal leiomyosarcoma found 5 cm in size: a case report. Hinyokika Kiyo. 2000, 46: 615-617.PubMedGoogle Scholar
- Kamba T, Kawakita M, Noguchi T, Kamoto T, Okabe T, Takeuchi E, Matsumoto M: Neoadjuvant CYVADIC (cyclophosphamide, vincristine, Adriamycin and dacarbazine) therapy for retroperitoneal leiomyosarcoma: a case report. Hinyokika Kiyo. 1997, 43: 577-580.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.